➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Dow
McKinsey
Mallinckrodt
Harvard Business School

Last Updated: August 13, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Solanezumab

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Solanezumab?

Solanezumab is an investigational drug.

There have been 10 clinical trials for Solanezumab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2010.

The most common disease conditions in clinical trials are Alzheimer Disease, Cognition Disorders, and Mild Cognitive Impairment. The leading clinical trial sponsors are Eli Lilly and Company, Hoffmann-La Roche, and Avid Radiopharmaceuticals.

There are thirteen US patents protecting this investigational drug and three hundred and sixty-one international patents.

Recent Clinical Trials for Solanezumab
TitleSponsorPhase
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's DiseaseEli Lilly and CompanyPhase 3
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)Eli Lilly and CompanyPhase 1
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory LossAlzheimer's Therapeutic Research InstitutePhase 3

See all Solanezumab clinical trials

Clinical Trial Summary for Solanezumab

Top disease conditions for Solanezumab
Top clinical trial sponsors for Solanezumab

See all Solanezumab clinical trials

US Patents for Solanezumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Solanezumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Solanezumab   Start Trial Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   Start Trial
Solanezumab   Start Trial Combination therapies for the treatment of Alzheimer's disease and related disorders The General Hospital Corporation (Boston, MA)   Start Trial
Solanezumab   Start Trial Methods of administering IgG1 antibodies and methods of suppressing angiogenesis University of Kentucky Research Foundation (Lexington, KY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Solanezumab

Drugname Country Document Number Estimated Expiration Related US Patent
Solanezumab Australia 2013220749 2032-02-15   Start Trial
Solanezumab Brazil 112014019627 2032-02-15   Start Trial
Solanezumab Canada 2862476 2032-02-15   Start Trial
Solanezumab China 104114705 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Dow
McKinsey
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.